TITLE

Sunovion: Latuda poised to expand options in bipolar depression

PUB. DATE
December 2012
SOURCE
PharmaWatch: CNS;Dec2012, Vol. 11 Issue 12, p14
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on the plan of Sunovion to expand options for the drug Latuda for depressive episodes in bipolar disorder. It cited the decision of the U.S. Food and Drug Administration (FDA) to review two supplemental New Drug Applications (sNDAs) for use of the drug as monotherapy and adjunctive therapy. The article also discusses the mechanism of action of Latuda as an atypical antipsychotic.
ACCESSION #
84110505

 

Related Articles

  • First antipsychotic medication endorsed for children and teens.  // Contemporary Pediatrics;Sep2007, Vol. 24 Issue 9, p23 

    The article reports on the approval of risperidone by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adolescents ages 13 to 17 on August 22, 2007. The drug can also be used as a short-term treatment of manic or mixed episodes of bipolar I disorder in children...

  • Sunovion Pharmaceuticals seeks FDA approval for LATUDA.  // PharmaWatch: CNS;Oct2012, Vol. 11 Issue 10, p13 

    The article reports that Sunovion Pharmaceuticals Inc. is seeking U.S. Food and Drug Administration (FDA) approval for the use of LATUDA, or lurasidone HCl, as monotherapy and adjunctive therapy to lithium or valproate. LATUDA is a treatment for adult patients with depressive episodes associated...

  • Sunovion receives FDA approval for expanded dose range of schizophrenia drug.  // PharmaWatch: CNS;Jun2012, Vol. 11 Issue 6, p22 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the expanded dose range for Sunovion Pharmaceuticals Inc.'s Latuda, a drug used to treat schizophrenia. It mentions that the highest recommended dose of the said drug was increased to 160 milligrams (mg) per day....

  • Sunovion Pharmaceuticals Receives Six Month U.S. Pediatric Exclusivity for LUNESTA(r) (eszopiclone).  // Biomedical Market Newsletter;7/26/2012, Vol. 21, p1 

    The article informs that Sunovion Pharmaceuticals Inc. has fulfilled the U.S. Food and Drug Administration (FDA) requirements for pediatric exclusivity for LUNESTA (eszopiclone) for the treatment of insomnia. It mentions that Sunovion has also gained an additional six months of U.S. market...

  • Pharma: Clinic Roundup.  // BioWorld Today;11/4/2013, Vol. 24 Issue 212, p9 

    The article reports that Marlborough, Massachusetts-based Sunovion Pharmaceuticals Inc. has published the results of their two trials on Latuda which supports the U.S. Food and Drug Administration's (FDA) drug approval as bipolar I disorder treatment.

  • Latuda Approved for Bipolar Depression.  // Monthly Prescribing Reference;Aug2013, Vol. 29 Issue 8, pA18 

    The article informs that the U.S. Food and Drug Administration (FDA) has approved two new indications for the Latuda durg for the treatment of bipolar disorder.

  • Approval for Geodon.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, pA11 

    The article reports on the approval of Geodon capsules from Pfizer Inc. for the adjunctive maintenance treatment of bipolar I disorder in adults by the U.S. Food and Drug Administration (FDA).

  • Quetiapine.  // AHFS Consumer Medication Information;Feb2020, p1 

    Quetiapine tablets and extended-release (long-acting) tablets are used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Quetiapine tablets and extended-release tablets are also...

  • Cariprazine: First Global Approval. McCormack, Paul // Drugs;Nov2015, Vol. 75 Issue 17, p2035 

    Cariprazine (Vraylarâ„¢) is an oral atypical antipsychotic originated by Gedeon Richter. It is a potent dopamine D and D receptor partial agonist, which preferentially binds to the D receptor. Cariprazine also has partial agonist activity at serotonin 5-HT receptors. In September 2015,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics